Selective B-Raf inhibitors such as Vemurafinib and Sorafenib that have been developed for the deregulated B-Raf malignancy in other tumor types (e. g. melanoma), can be used for management of approximately 8% of all PA harboring BRAFV600E mutation [14, 40]. The gene discussed is BRAF; the disease is neoplasm.